

Feidhmeannacht na Seirbhíse Sláinte, Seirbhís Aisíocaíochta Cúraim Phríomhúil Bealach amach 5 an M50, An Bóthar Thuaidh, Fionnghlas Baile Átha Cliath 11, D11 XKF3

Guthán: (01) 864 7100 Facs: (01) 834 3589

Health Service Executive, Primary Care Reimbursement Service Exit 5, M50, North Road, Finglas, Dublin 11, D11 XKF3 Tel: (01) 864 7100 Fax: (01) 834 3589

21 July 2020

Circular 022/20

Semaglutide (Ozempic®)

Dear Pharmacist,

I refer to previous correspondence in relation to Liraglutide (Victoza®) and reimbursement under Community Drug Schemes (Circular 45/19). As semaglutide (Ozempic®) is indicated for the treatment of Type II Diabetes Mellitus in the same manner as Victoza®, patients are entitled to be registered under the Long Term Illness (LTI) Scheme to enable them to obtain this product free of charge. The form can be downloaded at https://www2.hse.ie/file-library/long-term-illness/long-term-illness-schemeapplication-form.pdf.

Therefore, effective 1st August 2020, reimbursement will be confined to those persons with full GMS and LTI eligibility. Reimbursement of Ozempic® (GMS codes 33700, 33701 and 33702) will not be made available under the Drugs Payment Scheme (DPS) from this date.

Reimbursement support is available for the licensed indication and dosage only. Therefore, one pack of either the 0.25 mg / 0.5 mg / 1 mg strength provides a 4 weeks supply. The facility is available to pharmacies for 13 dispensing's' in a rolling 12 months to accommodate the shortfall.

Yours faithfully,

Shaun Flanagan

Primary Care Eligibility and Reimbursement